Marinosolv technology has shown to improve the solubility of active drug compounds-mometasone, fluticasone and fluorometholone-used to treat various diseases like asthma, inflammatory eye diseases and allergies, says Marinomed Biotech.
According to the company, Marinosolv enabled a 50 to 200-fold improvement in solubility which allows for poorly soluble active drug compounds to be dissolved in large quantities in recent preclinical studies.
“The new studies confirm that our clinically validated Marinosolv platform has enormous potential to change therapies in the fields of asthma, allergies and ophthalmology”, explains Marinomed CEO Andreas Grassauer in a statement.
The corticosteroids-mometasone, fluticasone and fluorometholone, may either be used to treat patients individually or in combination with other drugs. The preclinical studies also showed Marinosolv to facilitate the combination of different active ingredients.
Improved solubility results in higher amounts of the active ingredient at the target location such as eyes and nose with increased effectiveness even with reduced doses.
This facilitates potential new developments especially for fluticasone for the treatment of allergies and asthma, either as monotherapy or in combination with compounds from the class of antihistamines or bronchodilators. according to the release.